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Accepted 6 October 2017Background: Full body scintigraphy using bone tracers plays an important role in defining the type of amyloidosis
and in diagnosing the heart involvement (cardiac amyloidosis, CA). No study has been conducted to explore lung
retention (LR) in CA and its correlation to heart retention (HR).We evaluated LR in patients undergoing 99mTc-
HMDP scintigraphy during evaluation for suspected CA.
Methods and results:We enrolled 93 suspected CA patients. Patients underwent a complete diagnostic work up.
After diagnostic process 82 patients resulted affected by certain CA (20 AL and 62 TTR), while 11 subjects showed
left ventricular hypertrophy (LVH) not caused by CA. 99mTc-HMDP cardiac uptake was evaluated using the
Perugini visual score while the modified Janssen score was used for LR estimation (grade 0 no uptake, grade 1
less than ribs, grade 2 more than ribs).
Results: 99mTc-HMDP LR was observed in 1/20 AL patient (5%), while 36/62 (58%) TTR patients showed LR with
29 grade 1 (47%) and 7 grade 2 (11%). No LRwas observed in patients with LVH and no CA. LRwas not evident in
patients without HR, present in 1/3 (33%) of the patients with Perugini 1 HR and 11/24 (46%) and 26/36 (72%) of
the patients showing respectively a Perugini 2 and a Perugini 3.
Conclusion: 99mTc-HMDP scintigraphy shows LR in about 60% of TTR subjects, related to the grade of HR. In AL
amyloidosis LR is less frequent than in TTR amyloidosis suggesting an aetiological tropism that seems comparable
to the already known TTR related cardiac tropism.




Amyloidoses are rare diseases characterized by extracellular
deposition of protein-derived fibrils which show apple-green birefrin-
gence when stained with Congo red and viewed under polarized light
in various tissues and organs, including the heart [1].
Full body scintigraphy using bone tracers plays an important role in
defining the type of amyloidosis and in diagnosing the heart involve-
ment (cardiac amyloidosis, CA) [2–10].ability and freedom from bias of
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lli).Pathologically, involvement in the amyloid deposition of the respira-
tory tract is common [11–14] and may involve the lungs in 4 distinct
forms: lymphatic, diffuse alveolar septal, nodular parenchymal, and
tracheobronchial, with the former two patterns commonly present in pa-
tientswith systemic involvement and the latter two occurringmore com-
monly in localized forms. Systemic pulmonary amyloidosis is frequently
asymptomatic and dyspnoea, which is the leading symptom, ismainly at-
tributed to simultaneous cardiac involvement and heart failure.
Few reports have mentioned in the past bone tracers lung retention
both in patients with AL and TTR amyloidosis [15–18]. Nevertheless no
comprehensive study has been conducted to assess lung uptake in
systemic amyloidosis and its correlation with cardiac uptake. Moreover
to the best of our knowledge no study compared incidence and severity
of bone tracer scintigraphy lung retention in different aetiologies of
systemic amyloidosis.
Therefore the aim of our research has been to evaluate the presence
and grade of lung retention and its correlation to heart retention in a
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plinary evaluation for suspected cardiac amyloidosis.
2. Material and method
From the Tuscan regional amyloidosis centre database we retrospectively evaluated
all patients that underwent to 99mTc-HMDP total body scintigraphy as part of the usual
diagnostic workup to exclude or confirm a suspected cardiac amyloidosis. All patients
underwent physical examination, ECG, transthoracic echocardiography and blood tests
including NT-proBNP, serum and urinary immunifixation and serum free light chain. In
case of inconclusive results patients underwent cardiac MRI.
All patients gave written informed consent for their clinical records to be used for
research purposes, in accordance with Institutional Review Board guidelines.
2.1. Diagnosis of amyloidosis and cardiac involvement definition
Diagnosis of light-chain (AL) amyloidosis wasmade by biopsy of abdominal fat pad or
biopsy of an involved organ, which demonstrated the typical Congo Red birefringence
when viewed under polarized light. All positive biopsies demonstrated typical Congo
Red birefringence under polarized light and staining by anti-k or anti-λ light-chain anti-
bodies, combined with elevated serum or urine levels of the corresponding monoclonal
light chain.
Diagnosis of TTR amyloidosis was based on tissue biopsy with anti-TTR antibody
staining (irrespectively to bone scintigraphy cardiac uptake) or, in the absence of positive
tissue biopsy according to Gillmore et al. [19], by a Perugini grade 2 or 3 cardiac uptake on
a bone tracer radionuclide, and absence of a detectable monoclonal protein, in a patient
with echocardiogram and/or MRI suggestive of amyloidosis. Diagnosis of TTRm or
TTRwt was made according to the presence or absence of mutation at genotyping.
Diagnosis of cardiac amyloidosis was made according to the International Society of
Amyloidosis criteria [20].
Patients were considered to have left ventricular hypertrophy (LVH) not related
to amyloidosis infiltration if they had a negative cardiac biopsy or at least 2 negative
non-cardiac biopsies with no suggestive signs of cardiac amyloidosis at non-invasive
imaging evaluation (99mTc-HMDP total body scintigraphy, TTE and MRI) and absence
of amyloidogenic mutation at genotyping. In those patients further research to assess a
cause of LVH was performed.
2.2. Standard and tissue Doppler imaging echocardiography
Patientswere referred to our laboratory for echocardiographic study. Echocardiography
was performed using a Vivid 9 System (Vingmed, General Electric, Horten, Norway)
equipped with a 3S probe. According to the standards of the American Society of
Echocardiography [21], the following parameters were assessed: end-diastolic thickness
of interventricular septum (IVS) and LV posterior wall (PW), LV end-diastolic and end-
systolic volumes (LVEDV and LVESV, respectively), ejection fraction (estimated with the
biplane Simpson method), mitral peak flow velocity in early and late diastole (E and A, re-
spectively), E-wave deceleration time, E/A ratio, systolic displacement of the lateral portion
of the tricuspid annular plane systolic excursion (TAPSE). We also evaluated pulsed tissue
Doppler imaging-derived early diastolic peak velocity at mitral annulus (E′), and E/E′
ratio as an index of LV filling pressure. Pulmonary artery systolic pressure (PASP) was
approximated by adding to trans-tricuspid pressure gradient an estimate of right atrial
pressure assessed by inferior vena cava dimension and respiratory variation.
2.3. 99mTc-HMDP scintigraphy
All patients had 99mTc-HMDP whole body scintigraphy (HMDP-TB). 99mTc-HMDP
was prepared from the commercial kit (OSTEOCIS®) following the prescriptions of the
manufacturer.
All the preparations were tested for total hydrolysed and free 99mTc (b5%) and for
radiochemical purity (N95%).
Each patient received intravenous 700–740 MBq of 99mTc-HMDP and a whole body
scan (anterior and posterior projections) was performed 150 min later in a 256 ∗ 1024
matrix. Images were acquired in different gamma cameras using low energy, high
resolution collimators and an appropriate scan speed to reach over 2,000,000 count.
Each scintigraphy was evaluated with Perugini visual score as previously published
[2].
For lung uptake analysis a three degree modified and simplified Janssen [22] visual
score systemwas used: level 0 no significant lung uptake; level 1 light diffuse lung uptake
less than ribs; level 2 high and/or inhomogeneous lung uptake (Fig. 1). This grading
system resulted adequate to classify all patients of our series.
2.4. Chest X-ray radiological findings
In 49 patients, a recent chest X-ray (within 6months from scintigraphy)was available
and analyzed. Radiological findingswere classified according to a three level score: level 0
no significant interstitial changes; level 1 presence of modest/moderate interstitial
thickening or striations, no nodules; level 2 presence of significantly greater interstitial
thickening and/or striations and/or nodules.3. Statistical analysis
Continuous variables are expressed as median values and standard
deviation, and categorical variables as frequencies and percentages.
Multiple comparisons for continuous variables were performed with
ANOVA followed by Scheffè test for post hoc analyses. Categorical
comparisons were performed by means of the Pearson χ2 test.
All statistical analyses and comparisons were performed with
SPSS 20 Version IBM Package and we considered statistical significance
a p value b0.05.4. Results
Our study population consisted in 93 patients with suspected cardi-
ac amyloidosis. According to the above-mentioned criteria 82 patients
resulted affected by certain cardiac amyloidosiswhile after complete di-
agnostic workup 11 patients showed LVH not amenable to amyloid in-
filtration. In this subgroup 9 patients showed a hypertensive
cardiomyopathywhile in 2 patients a genetic confirmed diagnosis of hy-
pertrophic cardiomyopathy (HCM) was obtained.
Among patient with cardiac amyloidosis 20 patients had AL, 20 had
TTRm (6 patients with Val122Ile and 14 with Ile68Leu mutation), and
42 patients were affected by TTRwt. In AL patients, biopsy site was
abdominal fat in 19 patients (95%), myocardium in 1 (5%).
In TTRma positive biopsywas present in 16/20 patients and the pos-
itive biopsy site was abdominal fat in 11 patients (68%), myocardium in
5 (32%). In TTRwt a positive biopsy was present in 10/42 patients and
the positive biopsy site was abdominal fat in 5 patients, myocardium
in 5.
Demographic and clinical characteristics of the three groups are
summarized in Table 1.
As expected significant difference in agewas observed in the studied
population, with younger patients in the AL group. No significant
difference was observed between groups in heart failure symptoms
evaluated with New York Heart failure Association (NYHA) scale.
Similar echocardiographic variables were observed among the various
groups except for a significant increase in LV PW thickness in TTR
patients compared to LVH subjects.4.1. 99mTc-HMDP scintigraphy
As shown in Table 2 in AL cardiac amyloidosis, only 1 patient demon-
strated a mild heart retention at 99mTc-HMDP scintigraphy, Perugini
score grade 1, while 19 patients showed no bone tracer cardiac uptake.
On the other hand all patients with TTR cardiac amyloidosis showed
99mTc-HMDP heart uptake with 2 subjects showing a grade 1
Perugini visual score, 24 subjects a grade 2 and 36 subjects a grade 3.
No heart retention was evidenced in patients with LVH but no CA.
One patient with AL amyloidosis (5% of AL group) demonstrated
mild lung retention, grade 1 visual score, while 36 (58%) TTR patients
showed pulmonary uptake with 29 grade 1 and 7 grade 2 lung reten-
tion. No lung retention was evidenced in LVH subjects.
On a subgroup analysis lung uptake was not evident in patients
without cardiac uptake, present in 1/3 (33%) of the patients with
Perugini 1 cardiac uptake and 11/24 (46%) and 26/36 (72%) of the pa-
tients showing respectively a Perugini 2 and Perugini 3 cardiac uptake
(p b 0.001, Fig. 2).
Pulmonary uptake was uniform in all but one patient, without visu-
ally evident gradient between apical or basal portion of the lung. Only
one patient showed an inhomogeneous lung bone tracer retention
with patchy areas of hyperactivity.
Despite available only in a proportion of the studied population,
non-significant difference in radiological pulmonary score was
evidenced between groups.
Fig. 1.Examples illustrating the spectrumof 99mTc-HMDP lunguptake among patients using Janssenmodified visual score. (Left)No lunguptake (grade 0) and Perugini visual scoreHeart
Uptake 1, (centre) lung uptake less than ribs (grade 1) and Perugini visual score Heart Uptake 2, (right) lung uptake more than ribs (grade 2) and Perugini visual score Heart Uptake 2.
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In recent years radioactive bone tracers to diagnose cardiac
amyloidosis and amyloid typing have been extensively studied [2–4,19].
On the other hand the presence of bone tracer lung retention in
patients with AL and TTR amyloidosis has been far less investigated.Table 1
Demographic and clinical characteristics.
AL (n = 20) TTR (N = 62) LVH (N = 11) p=
Age 73.1 ± 11.9 79 ± 6.5 78.8 ± 8.7 0.02
Gender M/F 14/6 52/10 10/1 0.26
NYHA ≥ 3 12/20 (60%) 29/62 (46%) 6/11 (55%) 0.49
Creatinine mg/dl 0.99 ± 0.25 1.28 ± 0.44 1.27 ± 0.38 0.01
NT-proBNP ng/l 9762 ± 8688 5229 ± 4818 8246 ± 12,646 0.06
IVS mm 16.4 ± 1.5 17.3 ± 2.5 15.82 ± 2.6 0.18
PW mm 14.7 ± 1.9 16.3 ± 2.6 12.8 ± 1.6⁎ 0.001
LVEDV ml 73.7 ± 28.8 89.5 ± 26.9 99.2 ± 21.7 0.09
LVESV ml 36.2 ± 15.1 44.8 ± 22.1 41.3 ± 18.1 0.33
EF % 54.5 ± 11.5 50.9 ± 12.1 57.6 ± 8.4 0.40
E cm/s 79.0 ± 23.0 82.6 ± 15.5 88.2 ± 19.2 0.56
A cm/s 59.3 ± 25.1 50.1 ± 30.4 59.1 ± 26.7 0.43
E/A 1.7 ± 1.0 2.1 ± 0.97 1.69 ± 0.8 0.15
DT ms 171 ± 65 166 ± 41 197 ± 88 0.30
E/E′ 16.8 ± 6,1 17.7 ± 5.7 14.2 ± 6.2 0.17
PASP mm Hg 37.2 ± 10.9 36.2 ± 10.1 39.7 ± 13.4 0.71
TAPSE mm 16.1 ± 3.6 16.6 ± 3.8 19.1 ± 3.2 0.12
⁎ Post hoc analysis p b 0.05 TTR vs LVH.Our study for the first time demonstrated that in patients with TTR
amyloidosis, 99mTc-HMDP scintigraphy shows some grade of lung re-
tention in almost 60%of subjects.Moreover the incidence of lunguptake
seems to be significantly correlated to the grade of heart retention ac-
cording to Perugini visual score (Fig. 2). These data are in accordance
with the research of Hutt and co-authors which recently demonstrated
in a cohort of TTR amyloidosis patients, that soft tissue to femur ratio
was significantly different between each Perugini grade of 99mTc-DPD
scan, progressively increasing from grade 1 to grade 3 Perugini visual
score [23]. These data could therefore suggest that both soft tissue tracerTable 2









Score 0 19 0 11 0.0001
Score 1 1 2 0
Score 2 0 24 0
Score 3 0 36 0
Pulmonary uptake visual score
Score 0 19 26 11 0.0001
Score 1 1 29 0
Score 2 0 7 0
Pulmonary radiologic score (49pts)
Score 0 1 14 3 0.153
Score 1 3 19 –
Score 2 2 7 –
Fig. 2. 99mTc-HMDP lung uptake distribution according to heart uptake distribution using
Perugini visual score, in the whole population (p b 0.001).
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retention evaluated according to Perugini visual score.
The significant difference of distribution of 99mTc-HMPD lung up-
take in AL and TTR amyloidosis suggests an aetiological tropism, compa-
rable to the already well documented TTR related cardiac tropism. In
fact lung retention was evidenced only in one out of twenty patients
with AL amyloidosis, the only AL patient in our cohort, that also demon-
strated a simultaneous mild but clearly evident heart retention. Inter-
estingly no lung or heart retention was evidenced in the subgroup of
patients with LVH not amenable to cardiac amyloidosis.
The mechanism underling lung bone tracer uptake is not well
elucidated.
As previously suggested by Bach-Gansmo et al. [17] bone tracer lung
retention could reflect blood-pool activity or relatively high local
concentration in pulmonary tissue as part of soft tissue uptake in
systemic amyloidosis.
In our opinion the first hypothesis is far less convincing: if lung re-
tention was related to increased lung blood pool due to cardiac insuffi-
ciency, it should be similarly present in AL and LVH groups. In fact our
three groups presented comparable LV systolic and diastolic function,
RV longitudinal function and pulmonary systolic pressure. Moreover
NT-proBNP despite not significant, tends to be lower in patients with
TTR amyloidosis, the subgroup with the higher percentage of lung
99mTc-HMDP uptake.
Therefore 99mTc-HMDP pulmonary uptake could be more reason-
ably related to the presence of amyloid deposits in the lung. The in-
creased incidence of lung retention in TTR subjects could be due to the
highest tropism of 99mTc-HMDP for TTR amyloid deposit, a behaviour
already well documented for bone tracer heart retention [19].
Unfortunately the lack of lung biopsy or post mortem lung evalua-
tion let us only speculate on this hypothesis that should be confirmed
by further studies.
Irrespectively to the underlying mechanism, the presence of bone
tracer lung retention could lead to some technical concern. In fact a
diffuse and easy to perform quantitative method to assess bone trace
heart retention is based on the uptake ratio between cardiac region
and a specular region in the contralateral lung (H/CL ratio) [6,9,24].
The presence of lung uptake could drastically influence this quantitative
method, reducing the ratio between heart and lung. In our opinion iflung retention is evidenced, other quantitative methods such as heart
and whole body retention (H/WBR) ratio or heart to skull ratio (H/S)
[9] should be preferred.
6. Conclusions
The present findings demonstrated that in patients with TTR
amyloidosis, 99mTc-HMDP scintigraphy shows lung uptake in almost
60% of subjects. Lung uptake is significantly less frequent in AL amyloid-
osis patients, and completely absent in patients with LVH but without
CA.Moreover the incidence of lung uptake seems to be significantly cor-
related to the grade of heart retention according to Perugini visual score.
We can speculate that the increase incidence of lung retention in TTR
subjects could be explained by the highest tropism of 99mTc-HMDP
for TTR amyloid deposit, a behaviour already well documented for
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